Business
Novo Nordisk and Eli Lilly both think the Wegovy pill is doing well, but the American rival sees the successful launch as a harbinger of good news for its own candidate, orforglipron, which is expected to hit the market in the second quarter.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The mandatory work-from-home policy will remain in effect through March 31, but could be extended depending on circumstances.
Multiple pharma conferences set to take place in the United States this month will proceed as planned, but event organizers are urging precaution against the coronavirus.
AstraZeneca says the overrun is because of the complexity of the construction, inflation and other factors.
Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments for ophthalmic diseases, announced the appointment of Marcia de Souza Lima, M.D., M.I.P.P., as Chief Medical Officer.
Acacia Pharma Group plc, a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces the following changes to its Officers and Board of Directors.
Amalia Adler-Waxman, vice president of Social Impact and Responsibility at Teva, told BioSpace that the company believes everyone should have access to essential medications, regardless of their geographic location.
Ghosh succeeds current Unity CEO Keith Leonard, who will step down from his role. Leonard will continue as the chairman of the board of directors.
In addition, the company’s chief scientific officer, Seth Ettenberg, has resigned.
Qiagen manufactures diagnostic tests for a variety of diseases including cancer and, currently, the coronavirus that causes COVID-19.
Artificial intelligence and machine learning are increasingly becoming a part of drug discovery and development beginning with identifying new compounds to structuring and designing clinical trials and targeting clinical trial populations.